tbuckley/cabot-search huggingface dataset:
Cancer Signaling Drives Cancer Metabolism: AKT and the Warburg Effect
Authors: Aaron M. Hosios, Brendan D. Manning
Journal: Cancer Research (2021)

Abstract The Warburg effect, the propensity of some cells to metabolize glucose to lactate in the presence of oxygen (also known as aerobic glycolysis), has long been observed in cancer and other contexts of cell proliferation, but only in the past two decades have significant gains been made in understanding how and why this metabolic transformation occurs. In 2004, Cancer Research published a study by Elstrom and colleagues that provided one of the first connections between a specific oncogene and aerobic glycolysis. Studying hematopoietic and glioblastoma cell lines, they demonstrated that constitutive activation of AKT promotes an increased glycolytic rate without altering proliferation or oxygen consumption in culture. They proposed that it is this effect that allows constitutive AKT activation to transform cells and found that it sensitizes cells to glucose deprivation. In the years since, mechanistic understanding of oncogenic control of metabolism, and glycolysis specifically, has deepened substantially. Current work seeks to understand the benefits and liabilities associated with glycolytic metabolism and to identify inhibitors that might be of clinical benefit to target glycolytic cancer cells. See related article by Elstrom and colleagues, Cancer Res 2004;64:3892–9
How not to answer interdisciplinary “Why?” questions
Authors: Fred L Bookstein
Journal: Behavioral and Brain Sciences (2021)

Abstract The book under review tries to link the economic concept of “reward,” or, more accurately, “capture rate,” to the experimental literature of various neuroscientific quantities dealing with motor control. But this reviewer argues that such a linkage requires a richer language of quantification than the book actually affords: a language not just of “greater” or “less,” but of how much greater or less. Without such a methodology, the arguments here cannot be persuasive.
COVID-19, Hyperglycemia, and New-Onset Diabetes
Authors: Kamlesh Khunti, Stefano Del Prato, Chantal Mathieu, Steven E. Kahn, Robert A. Gabbay, John B. Buse
Journal: Diabetes Care (2021)

Certain chronic comorbidities, including diabetes, are highly prevalent in people with coronavirus disease 2019 (COVID-19) and are associated with an increased risk of severe COVID-19 and mortality. Mild glucose elevations are also common in COVID-19 patients and associated with worse outcomes even in people without diabetes. Several studies have recently reported new-onset diabetes associated with COVID-19. The phenomenon of new-onset diabetes following admission to the hospital has been observed previously with other viral infections and acute illnesses. The precise mechanisms for new-onset diabetes in people with COVID-19 are not known, but it is likely that a number of complex interrelated processes are involved, including previously undiagnosed diabetes, stress hyperglycemia, steroid-induced hyperglycemia, and direct or indirect effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the β-cell. There is an urgent need for research to help guide management pathways for these patients. In view of increased mortality in people with new-onset diabetes, hospital protocols should include efforts to recognize and manage acute hyperglycemia, including diabetic ketoacidosis, in people admitted to the hospital. Whether new-onset diabetes is likely to remain permanent is not known, as the long-term follow-up of these patients is limited. Prospective studies of metabolism in the setting of postacute COVID-19 will be required to understand the etiology, prognosis, and treatment opportunities.
499P The safety and efficacy of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)
Authors: M. Nakamura, A. Ishiguro, M. Dazai, Y. Kawamoto, S. Yuki, S. Sogabe, A. Hosokawa, K. Sawada, O. Muto, K. Umemoto, N. Izawa, K. Nakashima, M. Yagisawa, S. Kajiura, Y. Mitsuhashi, T. Ando, Y. Sunakawa, Y. Kikuchi, T. Yamanaka, Y. Komatsu
Journal: Annals of Oncology (2021)
908P Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
Authors: Y-K. Shi, L. Gao, Y. Tian, J. Chen, J. Wang, C. Bai, X. Li, H. Su, Z. Liu
Journal: Annals of Oncology (2021)
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences
Authors: Anneke D. van Dijk, Ti’ara L. Griffen, Yihua H. Qiu, Fieke W. Hoff, Endurance Toro, Kevin Ruiz, Peter P. Ruvolo, James W. Lillard, Eveline S. J. M. de Bont, Jan A. Burger, William Wierda, Steven M. Kornblau
Journal: Leukemia (2021)
1394P Frequentist and Bayesian analysis of second line treatment effectiveness in AGAMENON-SEOM gastric cancer registry
Authors: N. Martinez Lago, A. Carmona-Bayonas, A. Pieras Lopez, A. Ramchandani, F. Longo, A. Martin Carnicero, M. Granja Ortega, A. Calvo, R. Hernandez, N. Castro Unanua, J.D. Assaf, A. Azkarate, C. Hernandez-Perez, J.C. Camara, T. Saurí, A. Custodio, J.M. Cano, A. Fernandez Montes, E. Martinez de Castro, J. Gallego
Journal: Annals of Oncology (2021)
P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study
Authors: F. Camarda, F. Ardito, F. Lococo, M. Bensi, B. Di Stefano, M. Vellone, M. Chiappetta, M. Ribelli, A. Anghelone, F. Schietroma, G. Valente, C. Mele, D. Tabacco, M. Calegari, M. Basso, C. Pozzo, S. Margaritora, F. Giuliante, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2021)
751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
Authors: P. Corbaux, B. You, R.M. Glasspool, N. Yanaihara, A.V. Tinker, K. Lindemann, I.L. Ray-Coquard, M.R. Mirza, F. Subtil, O. Colomban, J. Peron, E. Karamouza, I. McNeish, S. Hinsley, T. Kagimura, S. Welch, L-A. Lewsley, X. Paoletti, A. Cook
Journal: Annals of Oncology (2021)
Disparities in COVID-19 Vaccination Status, Intent, and Perceived Access for Noninstitutionalized Adults, by Disability Status — National Immunization Survey Adult COVID Module, United States, May 30–June 26, 2021
Authors: A. Blythe Ryerson, Catherine E. Rice, Mei-Chuan Hung, Suchita A. Patel, Julie D. Weeks, Jennifer L. Kriss, Georgina Peacock, Peng-Jun Lu, Amimah F. Asif, Hannah L. Jackson, James A. Singleton
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Vaccine Recommendations and Guidelines of the Advisory Committee on Immunization Practices, CDC.https:
800P Tailoring adjuvant treatments in high-risk early stage endometrial cancer: Clinical outcomes of sequential chemoradiation in a real-word scenario
Authors: M. de Scordilli, M. Bartoletti, E. Palazzari, R. Mazzeo, A. Michelotti, M. Alberti, L. Gerratana, M.S. Nicoloso, S. Corsetti, S. Scalone, M. Gigante, S. Forte, N. Clemente, A. Del Fabro, E. Lucia, A. Ganis, G. Giorda, V. Canzonieri, R. Sorio, F. Puglisi
Journal: Annals of Oncology (2021)
Partha Kar: If you believe you can change it, prove it
Authors: Partha Kar
Journal: BMJ (2021)

Data and process are both key. Without outcomes, however, they become yet another paperwork driven exercise with no final product.

Healthcare, especially in the NHS, is blighted by such episodes. Despite having the right intentions, highlighting problems and developing processes, initiatives too often falter at the key bit: implementation to change outcomes. The problem is that, at some point, such repeated episodes culminate in stakeholder apathy and a loss of energy, or indeed a loss of belief among those whose lives you set out to improve.

The reports of the Workforce Race Equality Standard (WRES) have had that sort of feel. There’s no doubting the passion behind the initiative, the data, or the process. Yet the implementation of these best laid plans has faltered, raising the question of how much will be achieved by yet another …
Abstract 14778: The Impact of Scan Quality on the Diagnostic Performance of CCTA, SPECT and PET for Diagnosing Myocardial Ischemia as Defined by Fractional Flow Reserve - A PACIFIC-Trial Substudy
Authors: Pepijn A van Diemen, Roel S Driessen, Wynand J Stuijfzand, Pieter G Raijmakers, Stefan P Schumacher, James K Min, Jonathan A Leipsic, Juhani Knuuti, Richard S Underwood, Peter M van de Ven, Albert C van Rossum, Ibrahim Danad, Paul Knaapen
Journal: Circulation (2018)

Background: Scan quality of imaging modalities affects diagnostic accuracy, the magnitude of its impact on CCTA, SPECT, and PET for diagnosis of significant coronary artery disease (CAD) has scarce...
Covid-19: Spreading vaccine “misinformation” puts licence at risk, US boards tell physicians
Authors: Peter Doshi
Journal: BMJ (2021)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Covid-19: Spreading vaccine "misinformation" puts licence at risk, US boards tell physicians Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Comparative validation of machine learning algorithms for surgical workflow and skill analysis with the HeiChole benchmark
Authors: Martin Wagner, Beat-Peter Müller-Stich, Anna Kisilenko, Duc Tran, Patrick Heger, Lars Mündermann, David M Lubotsky, Benjamin Müller, Tornike Davitashvili, Manuela Capek, Annika Reinke, Carissa Reid, Tong Yu, Armine Vardazaryan, Chinedu Innocent Nwoye, Nicolas Padoy, Xinyang Liu, Eung-Joo Lee, Constantin Disch, Hans Meine, Tong Xia, Fucang Jia, Satoshi Kondo, Wolfgang Reiter, Yueming Jin, Yonghao Long, Meirui Jiang, Qi Dou, Pheng Ann Heng, Isabell Twick, Kadir Kirtac, Enes Hosgor, Jon Lindström Bolmgren, Michael Stenzel, Björn von Siemens, Long Zhao, Zhenxiao Ge, Haiming Sun, Di Xie, Mengqi Guo, Daochang Liu, Hannes G. Kenngott, Felix Nickel, Moritz von Frankenberg, Franziska Mathis-Ullrich, Annette Kopp-Schneider, Lena Maier-Hein, Stefanie Speidel, Sebastian Bodenstedt
Journal: Medical Image Analysis (2023)

Surgical workflow and skill analysis are key technologies for the next generation of cognitive surgical assistance systems. These systems could increase the safety of the operation through context-sensitive warnings and semi-autonomous robotic assistance or improve training of surgeons via data-driven feedback. In surgical workflow analysis up to 91% average precision has been reported for phase recognition on an open data single-center video dataset. In this work we investigated the generalizability of phase recognition algorithms in a multicenter setting including more difficult recognition tasks such as surgical action and surgical skill.To achieve this goal, a dataset with 33 laparoscopic cholecystectomy videos from three surgical centers with a total operation time of 22 h was created. Labels included framewise annotation of seven surgical phases with 250 phase transitions, 5514 occurences of four surgical actions, 6980 occurences of 21 surgical instruments from seven instrument categories and 495 skill classifications in five skill dimensions. The dataset was used in the 2019 international Endoscopic Vision challenge, sub-challenge for surgical workflow and skill analysis. Here, 12 research teams trained and submitted their machine learning algorithms for recognition of phase, action, instrument and/or skill assessment.F1-scores were achieved for phase recognition between 23.9% and 67.7% (n = 9 teams), for instrument presence detection between 38.5% and 63.8% (n = 8 teams), but for action recognition only between 21.8% and 23.3% (n = 5 teams). The average absolute error for skill assessment was 0.78 (n = 1 team).Surgical workflow and skill analysis are promising technologies to support the surgical team, but there is still room for improvement, as shown by our comparison of machine learning algorithms. This novel HeiChole benchmark can be used for comparable evaluation and validation of future work. In future studies, it is of utmost importance to create more open, high-quality datasets in order to allow the development of artificial intelligence and cognitive robotics in surgery.
269P Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
Authors: H.S. Rugo, A. Niyazov, H. Bhattacharyya, B. Arondekar, S.A. Hurvitz
Journal: Annals of Oncology (2021)
Is neural entrainment to rhythms the basis of social bonding through music?
Authors: Jessica A. Grahn, Anna-Katharina R. Bauer, Anna Zamm
Journal: Behavioral and Brain Sciences (2021)

Abstract Music uses the evolutionarily unique temporal sensitivity of the auditory system and its tight coupling to the motor system to create a common neurophysiological clock between individuals that facilitates action coordination. We propose that this shared common clock arises from entrainment to musical rhythms, the process by which partners' brains and bodies become temporally aligned to the same rhythmic pulse.
Abstract 3569: Genetic Contribution to Collagen-Induced Platelet Aggregation Following Low-Dose Aspirin in Families with Premature Coronary Artery Disease
Authors: J. Enrique Herrera-Galeano, Alexander F Wilson, Nauder Faraday, Lisa R Yanek, Taryn F Moy, Diane M Becker, Lewis C Becker
Journal: Circulation (2007)

Background: Lesser suppression by aspirin (ASA) of collagen-induced platelet aggregation predicts myocardial infarction and stroke. Variability in platelet aggregation to collagen was recently shown to be under genetic control; however, the specific genes that contribute to phenotypic variation are not known. Methods : We examined platelet function in 955 Caucasian (mean age 47+/−13.54, 52% female) and 541 African-American (mean age 45.71+/−12.7, 60% female) healthy subjects with a family history of early onset coronary artery disease (CAD). Collagen-induced platelet aggregation was measured by optical aggregometry after subjects were treated with low dose ASA (81 mg/day) for 2 weeks. 2638 single nucleotide polymorphisms (SNPs) from 191 candidate genes were evaluated using the Illumina platform. The ASSOC subroutine of SAGE was used to examine genotype-phenotype associations. To help discriminate true from false positive associations, while at the same time maintaining sensitivity, we propose a new approach in which SNPs are considered “significant” only when alpha &lt; 0.05 in both whites and blacks, combined with a locus specific heritability (LSH) ≥1% in both groups. Results: Using the Bonferroni correction to establish a p value threshold, no SNPs were associated with the phenotype. However, SNPs in 8 genes (ITGA2G, ITGB2, MAPK10, RAP1A, RGS10, VAV1, PEAR1 (platelet endothelial aggregation receptor 1), and PAFAH1B (platelet-activating factor acetylhydrolase) met the criteria of having significant p values in both groups, and SNPs in only 2 of the genes (PEAR1 and PAFAH1B) also contributed 31% to LSH (Table ). For both genes, the allele associated with a decreased response to ASA was the major allele among Caucasians, but the minor allele among African-Americans. Conclusions: Variants in PEAR1 and PAFAH1B are associated with decreased response to ASA in both African-Americans and Caucasians. Each contributes more than 1% to the genetic variance. Genotype Means and Variance contribution
1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma
Authors: R. Ramella Munhoz, V.P. de Camargo, G. Nader Marta, M.M. Queiroz, J. Cury-Martins, M. Nardo, C. Chaul-Barbosa, H. Ricci, M.R. de Mattos, T.A.F. de Menezes, G.U.D.C. Machado, E. Bertolli, M. Barros, F.A. Franke, F.D.O. Ferreira, O. Feher, G. de Castro
Journal: Annals of Oncology (2021)
1505MO Improving cancer care through broader access to quality biomarker testing: An IQN Path, ECPC and EFPIA initiative
Authors: N. Normanno, K. Apostolidis, M. Akkermans, R. Al Dieri, C. Bedard Pfeiffer, I. Cattaneo, Z.C. Deans, J. Emch, J.A. Fairley, P. Fivey, S. Hall, J. Maas, A. Martinez, H. Moch, S. Nielsen, T. Pilz, E. Rouleau, P.J. Simon, M. van Meerveld, N. Wolstenholme
Journal: Annals of Oncology (2021)
631P Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study
Authors: A. Rodriguez-Vida, J.P. Maroto Rey, A. Font Pous, C. Martin, B. Mellado, A. Corbera Lloret, M. Orrillo Sarmiento, O. Reig Torras, R. Querol Ninerola, L. Cano, A. Palazon, J. Alonso, S. Galtes, N. Juanpere, O. Juan, J. Bellmunt
Journal: Annals of Oncology (2021)
Transcriptional and functional divergence in lateral hypothalamic glutamate neurons projecting to the lateral habenula and ventral tegmental area
Authors: Mark A. Rossi, Marcus L. Basiri, Yuejia Liu, Yoshiko Hashikawa, Koichi Hashikawa, Lief E. Fenno, Yoon Seok Kim, Charu Ramakrishnan, Karl Deisseroth, Garret D. Stuber
Journal: Neuron (2021)
A summary of the updated report on the incidence and epidemiological trends of keratinocyte cancers in the UK 2013–2018
Authors: M. Kwiatkowska, S. Ahmed, M.R. Ardern‐Jones, L.A. Bhatti, T.O. Bleiker, A. Gavin, S. Hussain, D.W. Huws, L. Irvine, S.M. Langan, G.W.M. Millington, H. Mitchell, R. Murphy, L. Paley, C.M. Proby, C.S. Thomson, R. Thomas, C. Turner, S. Vernon, Z.C. Venables
Journal: British Journal of Dermatology (2021)

interactions.Participants described a relentless battle with rosacea, trying to conceal the visibility of their skin changes in order to be 'normal' and 'fit in with everyone else'.All participants described the financial impact of their perceived need to use different treatments and skincare products continuously, so as to try and 'stay on top of' their rosacea.On days when they felt they were losing 'the battle' and skin changes were visible, five participants described a sense of 'vulnerability', feeling 'like a second class of people', 'like a shell' and 'disgusting'.The accounts of participants reflected the importance of masking their difficulties from others as a way to defend against pain and emotional distress.When rosacea could not be concealed, five participants described being rejected by others, causing pain and emotional distress within some of their relationships.Uncertainty towards the cause of rosacea was reflected within all participants' transcripts.'Something I'd done', 'my fault', 'parasites', 'the immune system', 'hormones', 'pregnancy', 'genetics', 'old age' and 'God' were all indicated as factors thought to be associated with rosacea onset.While one participant described feeling 'scared' following her diagnosis, other accounts described how it helped the patients to make sense of their experiences, reducing feelings of 'embarrassment', 'blame' and 'shame' about their rosacea.The emotional, financial and social toll of living with rosacea was reflected in five participants' experiences and highlighted the importance of personal strength and resilience.In conclusion, this study has enriched our understanding of the lived experience of rosacea.We acknowledge the lack of representation of skin of colour, and would encourage further work of this type to explore the impact of rosacea in different ethnic groups.Participants in this study reflected feelings of low mood, anxiety, shame, rejection and embarrassment.Therefore, clinicians must be mindful of the psychosocial dimension, administering validated outcome measures to aid in the early detection of patient distress.When providing a diagnosis, clinicians may wish to offer a space where patients' initial thoughts, feelings and coping strategies can be explored.Realistic conversations about prognosis and the limited effectiveness of treatments may be helpful.Training and consultation may be beneficial to support the exploration of psychological distress and signposting to appropriate services.
Error in Visual Abstract
Journal: JAMA Network Open (2021)

Gilmar Reis, MD; Eduardo Augusto dos Santos Moreira Silva, MD; Daniela Carla Medeiros Silva, MD; Lehana Thabane, PhD; Gurmit Singh, PhD; Jay J. H. Park, MSc; Jamie I. Forrest, MPH; Ofir Harari, PhD; Castilho Vitor Quirino dos Santos; Ana Paula Figueiredo Guimarães de Almeida, MD; Adhemar Dias de Figueiredo Neto, MD; Leonardo Cançado Monteiro Savassi, MD; Aline Cruz Milagres, RN; Mauro Martins Teixeira, MD; Maria Izabel Campos Simplicio, BScPharm; Luciene Barra Ribeiro, RN; Rosemary Oliveira; Edward J. Mills, PhD; TOGETHER Investigators
Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
Authors: Anneli Andersson, Matt Kelly, Kento Imajo, Atsushi Nakajima, Jonathan A. Fallowfield, Gideon Hirschfield, Michael Pavlides, Arun J. Sanyal, Mazen Noureddin, Rajarshi Banerjee, Andrea Dennis, Stephen Harrison
Journal: Clinical Gastroenterology and Hepatology (2021)

Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. NAFLD is associated with excess risk of all-cause mortality, and its progression to nonalcoholic steatohepatitis (NASH) and fibrosis accounts for a growing proportion of cirrhosis and hepatocellular cancer and thus is a leading cause of liver transplant worldwide. Noninvasive precise methods to identify patients with NASH and NASH with significant disease activity and fibrosis are crucial when the disease is still modifiable. The aim of this study was to examine the clinical utility of corrected T1 (cT1) vs magnetic resonance imaging (MRI) liver fat for identification of NASH participants with nonalcoholic fatty liver disease activity score ≥4 and fibrosis stage (F) ≥2 (high-risk NASH).Data from five clinical studies (n = 543) with participants suspected of NAFLD were pooled or used for individual participant data meta-analysis. The diagnostic accuracy of the MRI biomarkers to stratify NASH patients was determined using the area under the receiver operating characteristic curve (AUROC).A stepwise increase in cT1 and MRI liver fat with increased NAFLD severity was shown, and cT1 was significantly higher in participants with high-risk NASH. The diagnostic accuracy (AUROC) of cT1 to identify patients with NASH was 0.78 (95% CI, 0.74-0.82), for liver fat was 0.78 (95% CI, 0.73-0.82), and when combined with MRI liver fat was 0.82 (95% CI, 0.78-0.85). The diagnostic accuracy of cT1 to identify patients with high-risk NASH was good (AUROC = 0.78; 95% CI, 0.74-0.82), was superior to MRI liver fat (AUROC = 0.69; 95% CI, 0.64-0.74), and was not substantially improved by combining it with MRI liver fat (AUROC = 0.79; 95% CI, 0.75-0.83). The meta-analysis showed similar performance to the pooled analysis for these biomarkers.This study shows that quantitative MRI-derived biomarkers cT1 and liver fat are suitable for identifying patients with NASH, and cT1 is a better noninvasive technology than liver fat to identify NASH patients at greatest risk of disease progression. Therefore, MRI cT1 and liver fat have important clinical utility to help guide the appropriate use of interventions in NAFLD and NASH clinical care pathways.
LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10
Authors: A. Papachristofilou, J. Bedke, S. Hayoz, U. Schratzenstaller, M. Pless, M. Hentrich, S. Krege, A. Lorch, D.M. Aebersold, P-M. Putora, D.R. Berthold, D. Zihler, N.C. Azinwi, F. Zengerling, A. Dieing, A-C. Mueller, C. Schaer, C. Biaggi, S. Gillessen, R. Cathomas
Journal: Annals of Oncology (2021)